CSF2 and rheumatoid arthritis: CS-ESP treatment notably reduced the production of pro-inflammatory cytokines such as IL-17A and GM-CSF in peripheral blood mononuclear cells (PBMCs) from RA and AS patients, without affecting cell viability.